SANTA CRUZ BIOTECHNOLOGY, INC.

FLJ46358 (N-17): sc-246938

SANTA CRUZ BIOTECHNOLOGY

The Power to Question

BACKGROUND

FLJ46358 is a 259 amino acid protein that is encoded by a gene located on human chromosome 13q12.12. Chromosome 13 comprises nearly 4% of human DNA and contains about 114 million base pairs and 400 genes. Key tumor suppressor genes on chromosome 13 include the breast cancer susceptibility gene, BRCA2, and the RB1 (retinoblastoma) gene. RB1 encodes a crucial tumor suppressor protein which, when defective, leads to malignant growth in the retina and has been implicated in a variety of other cancers. The gene SLITRK1, which is associated with Tourette syndrome, is on chromosome 13. As with most chromosomes, polysomy of part or all of chromosome 13 is deleterious to development and decreases the odds of survival.

REFERENCES

1. Dunham, A., et al. 2004. The DNA sequence and analysis of human chromosome 13. Nature 428: 522-528.
2. Deng, H., et al. 2006. Examination of the SLITRK1 gene in Caucasian patients with Tourette syndrome. Acta Neurol. Scand. 114: 400-402.
3. Giacinti, C. and Giordano, A. 2006. RB and cell cycle progression. Oncogene 25: 5220-5227.
4. Grados, M.A. and Walkup, J.T. 2006. A new gene for Tourette's syndrome: a window into causal mechanisms? Trends Genet. 22: 291-293.
5. Bugge, M., et al. 2007. Non-disjunction of chromosome 13. Hum. Mol. Genet. 16: 2004-2010.
6. Hsu, H.F. and Hou, J.W. 2007. Variable expressivity in Patau syndrome is not all related to trisomy 13 mosaicism. Am. J. Med. Genet. A 143: 1739-1748.
7. Hall, H.E., et al. 2007. The origin of trisomy 13. Am. J. Med. Genet. A 143: 2242-2248.
8. Hassler, M., et al. 2007. Crystal structure of the retinoblastoma protein N domain provides insight into tumor suppression, ligand interaction and holoprotein architecture. Mol. Cell 28: 371-385.
9. Thorslund, T. and West, S.C. 2007. BRCA2: a universal recombinase regulator. Oncogene 26: 7720-7730.

CHROMOSOMAL LOCATION

Genetic locus: ANKRD20A19P (human) mapping to 13q12.12.

SOURCE

FLJ46358 (N-17) is an affinity purified goat polyclonal antibody raised against a peptide mapping near the N-terminus of FLJ46358 of human origin.

PRODUCT

Each vial contains 200 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-246938 P, (100 µg peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

FLJ46358 (N-17) is recommended for detection of FLJ46358 of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Molecular Weight of FLJ46358: 28 kDa.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.